On December 7, 2023, Juncell Therapeutics today announced the publication of abstracts reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the ESMO IMMUNO-ONCOLOGY Congress 2023 in Geneva, Switzerland, December 6-8, 2023. The details of the abstract are as follows:

Abstract #63TiP: A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen : MIZAR trial

Presentation Type: Trial in Progress (TiP) Poster

About MIZAR trial

MIZAR trial (GC101 TIL-ST-01, NCT05417750) is a phase 1, open label, nonrandomized, multicohort, multicenter study evaluating GC101 in patients with advanced solid tumors. The NMPA allowed an Investigational New Drug (IND) Application to proceed in April 2022.

Juncell Contact:

contact@juncell.com